An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of psoriatic arthritis (PsA) in Europe, the USA, and Latin American countries. CZP neutralizes TNF-α at its soluble and membrane portions. Due to the lack of Fc region, it does not i...

Descripción completa

Detalles Bibliográficos
Autores principales: Acosta-Felquer, María Laura, Rosa, Javier, Soriano, Enrique R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098767/
https://www.ncbi.nlm.nih.gov/pubmed/27843368
http://dx.doi.org/10.2147/OARRR.S56837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098767/
https://www.ncbi.nlm.nih.gov/pubmed/27843368
http://dx.doi.org/10.2147/OARRR.S56837

Ejemplares similares